NCT03524339

Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

Perioperative Administration of Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 132 (actual)
• Sponsor: University Hospitals Cleveland Medical Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a placebo controlled randomized controlled trial of perioperative use of tamsulosin to prevent postoperative urinary retention in female pelvic reconstructive surgery.

Conditions

• Urinary Retention
• Lower Urinary Tract Symptoms
• Stress Urinary Incontinence
• Pelvic Organ Prolapse

Interventions

Type	Name	Description
DRUG	Placebo oral capsule	Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
DRUG	Tamsulosin	Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.

Timeline

• Start date: 2018-08-01
• Primary completion: 2020-06-09
• Completion: 2020-06-09
• First posted: 2018-05-14
• Last updated: 2021-11-08
• Results posted: 2021-11-08

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study